Zimmer Biomet Holdings, Inc. Share Price

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:02 14/06/2024 BST 5-day change 1st Jan Change
107.2 USD +0.21% Intraday chart for Zimmer Biomet Holdings, Inc. -5.43% -11.92%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 7.76B 612B Sales 2025 * 8.12B 640B Capitalization 22.05B 1,738B
Net income 2024 * 998M 78.67B Net income 2025 * 1.2B 94.52B EV / Sales 2024 * 3.4 x
Net Debt 2024 * 4.32B 341B Net Debt 2025 * 2.99B 236B EV / Sales 2025 * 3.09 x
P/E ratio 2024 *
22 x
P/E ratio 2025 *
18.9 x
Employees 18,000
Yield 2024 *
0.9%
Yield 2025 *
0.91%
Free-Float 64.77%
More Fundamentals * Assessed data
Dynamic Chart
Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health MT
RevelAi Health and Zimmer Biomet Holdings, Inc. Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity Through AI-Powered Technology CI
Transcript : Zimmer Biomet Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
Zimmer Biomet Enters Distribution Agreement with THINK Surgical to Offer TMINI Miniature Handheld Robotic System for Total Knee Arthroplasty CI
Osteal Therapeutics, Inc. announced that it has received $50 million in funding from Zimmer Biomet Holdings, Inc., Johnson & Johnson Innovation - JJDC, Inc., HM Capital Management, LLC, GIDEON STRATEGIC PARTNERS LLC and other investors CI
Zimmer Biomet Holdings Insider Sold Shares Worth $1,474,582, According to a Recent SEC Filing MT
Zimmer Biomet's Limited Exposure to High-Growth Markets Spurs Revenue Concerns, UBS Says MT
Barclays Adjusts Price Target on Zimmer Biomet to $125 From $130 MT
Barclays Adjusts Price Target on Zimmer Biomet Holdings to $125 From $130 MT
Zimmer Biomet Outlines Growth Strategy Through 2027; Board Approves $2 Billion Stock Buyback MT
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $2,000 million worth of its shares. CI
Transcript : Zimmer Biomet Holdings, Inc. - Analyst/Investor Day
Zimmer Biomet Holdings, Inc. authorizes a Buyback Plan. CI
Osteal Therapeutics, Inc. announced that it expects to receive funding CI
Argus Upgrades Zimmer Biomet to Buy From Hold With $150 Price Target MT
More news
1 day+0.21%
1 week-5.43%
Current month-6.91%
1 month-11.40%
3 months-14.36%
6 months-9.69%
Current year-11.92%
More quotes
1 week
106.01
Extreme 106.01
113.25
1 month
106.01
Extreme 106.01
121.30
Current year
106.01
Extreme 106.01
133.90
1 year
102.00
Extreme 102
147.50
3 years
100.39
Extreme 100.39
167.59
5 years
74.37
Extreme 74.37
180.36
10 years
74.37
Extreme 74.37
180.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 31/10/18
Director of Finance/CFO 55 30/06/19
Chief Tech/Sci/R&D Officer - 06/06/21
Members of the board TitleAgeSince
Director/Board Member 68 31/12/06
Director/Board Member 68 31/12/08
Director/Board Member 51 11/12/14
More insiders
Date Price Change Volume
14/06/24 107.2 +0.21% 1,611,412
13/06/24 107 -0.45% 1,470,959
12/06/24 107.4 -1.63% 2,996,456
11/06/24 109.2 -3.23% 3,036,000
10/06/24 112.9 -0.41% 1,214,510

Delayed Quote Nyse, June 14, 2024 at 09:00 pm

More quotes
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
107.2 USD
Average target price
136.4 USD
Spread / Average Target
+27.23%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW